Mind Medicine Newsroom

Mind Medicine Price Target Announced at $20.00/Share by Chardan Capital

Dow JonesDec 20 19:27

Mind Medicine Initiated at Buy by Chardan Capital

Dow JonesDec 20 19:27

Mind Medicine Analyst Ratings

BenzingaDec 18 00:12

Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20

Futu NewsDec 17 21:33

Mind Medicine (MNMD) Receives a Buy From Oppenheimer

TipRanksDec 17 20:48

RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $21

Futu NewsNov 20 23:31

RBC Capital Remains a Buy on Mind Medicine (MNMD)

TipRanksNov 20 23:16

Mind Medicine Analyst Ratings

BenzingaNov 11 18:20

Maxim Group Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $18

Futu NewsNov 10 01:32

Oppenheimer Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $20

Futu NewsNov 10 00:31

H.C. Wainwright Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $55

Futu NewsNov 10 00:31

Mind Medicine's Strategic Advancements and Clinical Progress Drive Buy Rating

TipRanksNov 9 01:19

CCORF Maintains Mind Medicine(MNMD.US) With Buy Rating, Raises Target Price to $16

Futu NewsNov 8 21:32

RBC Capital Maintains Mind Medicine(MNMD.US) With Buy Rating, Cuts Target Price to $21

Futu NewsNov 8 20:35

Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), Knight Therapeutics (OtherKHTRF) and OnKure Therapeutics (OKUR)

TipRanksNov 8 20:12

RBC Capital Keeps Their Buy Rating on Mind Medicine (MNMD)

TipRanksNov 8 20:12

Leerink Partners Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $20

Futu NewsOct 12 06:31

Mind Medicine Is Maintained at Buy by Canaccord Genuity

Dow JonesSep 16 22:29

Mind Medicine Analyst Ratings

BenzingaAug 29 20:04

HC Wainwright & Co. Maintains Buy on Mind Medicine, Raises Price Target to $55

BenzingaAug 29 20:04